Is Lyrica (Pregabalin) Safe with Ketamine?

If you're on Lyrica (pregabalin) and considering at-home ketamine therapy, the combination is safe at all standard doses. Lyrica is in the same drug class as gabapentin (gabapentinoids) and shares the same mechanism, so the conclusions on the gabapentin page apply here directly: continue Lyrica throughout your ketamine course, with brief attention to sedation timing at higher doses. The Lyrica-specific notes are slight pharmacokinetic differences from gabapentin and the Schedule V controlled-substance status, neither of which changes the verdict.

What Lyrica is and what makes it different from gabapentin

Lyrica (pregabalin) and Neurontin (gabapentin) are both gabapentinoids, a small drug class that works on the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. The mechanism reduces presynaptic neurotransmitter release in certain pain and anxiety pathways. Both drugs are FDA-approved for similar indications (postherpetic neuralgia, partial-onset seizures, fibromyalgia for Lyrica only, diabetic neuropathic pain for Lyrica) and are widely prescribed off-label for generalized anxiety, insomnia, and various other neuropathic pain conditions.

The clinical differences between Lyrica and gabapentin are subtle but worth knowing: Lyrica is approximately 2-3 times more potent per milligram, so dosing is at lower numbers (75-600 mg/day Lyrica versus 300-3600 mg/day gabapentin). Lyrica has linear pharmacokinetics, meaning doubling the dose reliably doubles the plasma level; gabapentin saturates its absorption at higher doses, producing nonlinear pharmacokinetics that make precise dosing harder. Lyrica is a Schedule V controlled substance in the US (gabapentin is not federally scheduled, though some states have moved to schedule it). For ketamine combination, none of these differences change the verdict.

What the published evidence shows

The general antidepressant + ketamine evidence base applies in full to patients on Lyrica. The Veraart 2021 systematic review (PMID 34170315) did not identify pregabalin or other gabapentinoids as a documented case-series risk and did not extend its benzo/Z-drug minimization recommendation to gabapentinoids. The Curran 2026 outcomes study (DOI 10.4088/JCP.25br16294) included pregabalin-treated patients without reporting differential outcomes. The Alnefeesi 2022 real-world meta-analysis (PMID 35688035) pooled 2,665 TRD patients with pregabalin commonly prescribed in the chronic-pain-and-depression population.

No pregabalin-specific case reports of serotonin syndrome, hypertensive crisis, or other adverse outcomes from at-home ketamine combination exist in the published literature.

For seizure threshold: Lyrica is FDA-approved for partial-onset seizure prophylaxis, and ketamine at therapeutic doses has an anticonvulsant rather than pro-convulsant profile per the Shehata 2024 systematic review (PMID 38293492). Combining the two does not compound seizure risk.

Why the GABA-A mechanism point matters here too

The same caveat we covered on the gabapentin page applies to Lyrica: the name and the anti-anxiety effect can suggest similarity to benzodiazepines, but the mechanism is fundamentally different. Lyrica doesn't bind GABA receptors at all. The Veraart 2021 systematic review's recommendation to "minimize benzodiazepine (and Z-drug) use in patients receiving ketamine for depression" is mechanism-specific to GABA-A receptor binders and does not extend to gabapentinoids.

This matters because some patients on Lyrica for anxiety mistakenly think their medication is in the same category as Xanax for ketamine purposes and consider stopping it. They shouldn't. Continue your Lyrica throughout the ketamine course.

The sedation-timing note

Lyrica can be meaningfully sedating, particularly at higher doses and in the first 2-3 hours after a dose. Standard low-to-moderate doses (75-300 mg/day total, typically split into 2-3 daily doses) produce mild sedation that doesn't typically require timing adjustment for ketamine sessions. Higher doses (300-600 mg/day, common in fibromyalgia or chronic pain) can be more substantially sedating, and we suggest scheduling daytime ketamine sessions at least 2-3 hours after a Lyrica dose. For most patients on three-times-daily Lyrica, this means scheduling sessions for the late morning after the morning dose's peak has passed.

What we do at intake

When a patient is on Lyrica, our intake process for ketamine includes:

The total daily dose. 75 mg to 600 mg/day depending on indication.

The dosing schedule. Twice daily or three times daily are most common.

The indication. Fibromyalgia, postherpetic neuralgia, diabetic peripheral neuropathy, generalized anxiety (off-label in the US, on-label in EU), partial-onset seizures, or other neuropathic pain.

How long you've been on the current dose. Stable for at least 4-6 weeks is most common.

The prescribing physician relationship. For chronic pain or seizure indications, we coordinate with the prescribing physician.

For most patients on stable Lyrica, this is a brief conversation and we proceed with standard ketamine onboarding.

Tapering: not for ketamine

Lyrica's discontinuation syndrome can be more pronounced than gabapentin's because of the higher per-mg potency and the rapid clearance after the calcium channel binding releases. Abrupt stopping can produce rebound pain or anxiety, sleep disturbance, headache, nausea, and rarely seizures. Tapering should be gradual and supervised. There is no reason to taper Lyrica for ketamine purposes; continuing throughout the course is the standard approach.

Bottom line

Lyrica at all standard doses is safe to combine with at-home ketamine therapy. The mechanism is alpha-2-delta calcium channel modulation, not GABA-A binding, so the benzo attenuation of ketamine response does not apply. The only operational consideration is sedation timing at higher doses, which is straightforward to accommodate. Continue your current Lyrica regimen throughout the ketamine course; tapering decisions belong with your prescribing physician on their own clinical merits.